Version 1
: Received: 23 August 2024 / Approved: 26 August 2024 / Online: 26 August 2024 (20:14:17 CEST)
How to cite:
KARA, F.; Kantarci, K. Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype. Preprints2024, 2024081848. https://doi.org/10.20944/preprints202408.1848.v1
KARA, F.; Kantarci, K. Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype. Preprints 2024, 2024081848. https://doi.org/10.20944/preprints202408.1848.v1
KARA, F.; Kantarci, K. Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype. Preprints2024, 2024081848. https://doi.org/10.20944/preprints202408.1848.v1
APA Style
KARA, F., & Kantarci, K. (2024). Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype. Preprints. https://doi.org/10.20944/preprints202408.1848.v1
Chicago/Turabian Style
KARA, F. and Kejal Kantarci. 2024 "Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype" Preprints. https://doi.org/10.20944/preprints202408.1848.v1
Abstract
In vivo proton (1H) magnetic resonance spectroscopy (MRS) is a powerful noninvasive method which can measure Alzheimer’s disease (AD) related neuropathological alterations at the molecular level. AD biomarkers include amyloid-beta (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles. These biomarkers can be detected via postmortem analysis, but also in living individuals through positron emission tomography (PET) or biofluid biomarkers of Aβ and tau. This review offers an overview of biochemical abnormalities detected by 1H MRS within the biologically defined AD spectrum. It includes a summary of earlier studies that explored the association of 1H MRS metabolites with biofluid, PET, and postmortem AD biomarkers, and examined how apolipoprotein e4 allele carrier status influences brain biochemistry. Studying these associations is crucial for understanding how AD pathology affects brain homeostasis throughout the AD continuum and may eventually facilitate to develop potential novel therapeutic approaches.
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
